Biosimilars Would Have Medicare Parity With Innovators Under Reform Bill

The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23